Efficacy of autologous platelets in macular hole surgery

Aristeidis Konstantinidis^{1,2}

Mark Hero²

Panagiotis Nanos¹

Georgios D Panos^{1,3}

¹Department of Ophthalmology, University Hospital of Alexandroupolis, Alexandroupolis, Greece; ²Ophthalmology Department, University Hospital Coventry and Warwickshire, Coventry, UK; ³Department of Ophthalmology, University Hospitals of Geneva, Geneva, Switzerland

Abstract: The introduction of optical coherence tomography has allowed accurate measurement of the size of macular holes. A retrospective consecutive review was performed of 21 patients undergoing macular hole repair with vitrectomy, gas tamponade, and autologous platelet injection and we assessed the effect of macular hole parameters on anatomic and functional outcomes. We looked at the demographic features, final visual outcome, and anatomical closure. Twenty-one patients were included in the study. They underwent routine vitrectomy with gas tamponade (C₃F₈) and injection of autologous platelets. All patients were advised to maintain a facedown posture for 2 weeks. Anatomical closure was confirmed in all cases and 20 out of 21 of patients had improved postoperative visual acuity by two or more lines. In our series, the macular hole dimensions did not have much effect on the final results. The use of autologous platelets and strict facedown posture seems to be the deciding factor in good anatomical and visual outcome irrespective of macular hole dimensions.

Keywords: macular hole, platelets, vitrectomy

Introduction

Macular hole is a defect in the macular retina involving its full thickness from the internal limiting membrane (ILM) to the outer segment of the photoreceptor layer. It was first described in the ophthalmic literature in 1869 by Herman Knapp in a patient who suffered blunt injury in the eye.¹ Macular holes are identified and staged with slit-lamp biomicroscopy. The introduction of optical coherence tomography (OCT) has further enhanced the assessment of the topographical details of macular holes.^{2,3} For over a century it was not believed to be treatable until 1991 when Kelly and Wendel reported a series of patients with macular holes treated with vitrectomy, gas tamponade, and facedown position.⁴ Previous studies have shown a relationship of the Macular Hole Index⁵ and the Hole Form Factor⁶ to a successful outcome. Our study was aimed to look at a possible relation of the macular hole depth to a favorable anatomical and visual outcome as well as the effect of autologous platelet injection in the surgical repair of macular holes.

Subjects and methods

This is a retrospective study. It included 21 eyes of 21 consecutive patients with idiopathic full-thickness macular holes between November 2004 and February 2006. Patients with other coexisting macular pathologies such as macular degeneration or diabetic maculopathy were not included in the study. All patients were operated on by a single surgeon (MH). Informed consent was not obtained from the patients as OCT

Correspondence: Georgios D Panos
Department of Ophthalmology,
University Hospitals of Geneva,
Rue Alcide – Jentzer 22, 1211,
Geneva, Switzerland
Tel +41 79 55 34 739
Fax +41 22 382 83 82
Email georgios.panos@hcuge.ch

scans are routinely performed for patients with macular holes pre- and postoperatively. The study has been performed in accordance with the ethical standards of the Declaration of Helsinki.

Detailed history including duration of symptoms was obtained from each patient. After checking the best-corrected visual acuity (BCVA) with the Snellen chart (visual acuities were later converted to logMAR) and the intraocular pressure (IOP), the pupils were dilated. BCVA was measured with subjective and objective refraction by an experienced optometrist at the time that a patient was listed for surgery and at 6 months postoperatively. All patients then underwent slit-lamp examination to determine the status of the lens (phakic, aphakic, or pseudophakic) and assessment of the macula (noncontact biomicroscopy with 90D and contact biomicroscopy with Goldmann 3 mirror lens [Haag-Streit, Bern, Switzerland]).

OCT was then performed through a dilated pupil. The imaging involved multiple horizontal and vertical 5 mm scans with the fixation maintained. The OCT machine used was the Stratus OCT III version 5 (Carl Zeiss Meditec, Jena, Germany).

The macular hole diameters measured using the OCT were at the level of retinal pigment epithelium (maximum diameter), at the minimum extent of the hole (minimum diameter), and finally at the surface of the hole (rim diameter). The depth of the hole was also measured (Figure 1). There were one stage II, 17 stage III, and three stage IV macular holes.

All the patients underwent 23G three-port pars plana vitrectomy, autologous platelets injection followed by injection of gas tamponade (20% C₃F₈). All phakic patients (15 out of 21) also had phacoemulsification with posterior chamber implant combined with the above procedure. One hour after the surgery, the patients were asked to maintain a facedown posture (FDP) for 2 weeks, starting from the first postoperative day. The patients were instructed to maintain a FDP 45 minutes every hour.

Figure 1 Macular hole parameters.

Notes: (a) rim diameter, (b) minimum diameter, (c) maximum diameter, and (d) height.

The autologous platelet concentrate (APC) was prepared as described by previous authors.^{7,8} Fifty microliters of venous blood were drawn 1 hour before the operation. This blood sample was mixed with 6 mL of acid citrate dextrose and centrifuged at 280 g (1500 rpm) for 15 minutes. The platelet-rich plasma was then extracted and mixed with 1/8 volume of acid citrate dextrose and centrifuged again at 1000 g for 10 minutes. Finally, the platelet concentrate was mixed with 0.6 mL of sodium chloride. Two drops of 0.1 mL each were then injected in the eye. ILM peel was not attempted in any patient, as this technique was not favored by the operating surgeon.

Visual acuity, IOP and slit-lamp biomicroscopy were carried out on the first postoperative day, 1 week, 12 weeks, and 6 months after surgery. OCT was repeated at 1 month and 6 months. Postoperative anatomical success was defined as closure of the hole with no subretinal fluid at 6 months postoperatively. Pre- and postoperative BCVA were measured and compared in relation to the preoperative macular hole parameters.

Pearson's correlation coefficient was used to search for an existing relationship between BCVA at 6 months, BCVA improvement and macular hole parameters. $P < 0.05$ showed statistical significance. All statistics were performed using MedCalc software (version 10.2; MedCalc, Ostend, Belgium).

Results

A total of 21 eyes of 21 patients (male, 6; female, 15) were included in the study. Their age ranged from 56 to 77 years with a mean of 66.6 years. The majority of patients were phakic (15 out of 21) and six had uncomplicated cataract surgery with posterior chamber intraocular lens implant. The OCT parameters measured were: rim diameter (range: 299–1,372 μ ; mean: 697 μ), maximum diameter (range: 336–1,384 μ ; mean: 755 μ), minimum diameter (range: 207–798 μ ; mean: 402 μ), and thickness (range: 113–805 μ ; mean: 407 μ) (Table 1).

Preoperative BCVA ranged from 1.3 to 0.5 logMAR with the majority of patients (20 out of 21) having an acuity from 1.3–0.8 logMAR. All the patients were followed up for 8 to 10 months after the operation. However, for the purpose of the study final outcomes (BCVA, confirmation of macular hole closure, reopening of the macular hole) were assessed at 6 months postoperatively. At that time their BCVA ranged from 0.0 to 0.8 log MAR with the majority of patients (18 out of 21) having a BCVA between 0.5 and 0.6 logMAR. Twenty out of 21 patients had improvement in visual acuity by two or

Table 1 Patients' characteristics and macular hole parameters^a

Patient	Sex	Age	Lens status	Rim diameter	Minimum diameter	Maximum diameter	Thickness	Preop VA	Postop VA
1	F	61	Phakic	898	509	935	457	0.8	0.2
2	F	66	Phakic	361	224	442	332	1.0	0.5
3	F	75	Pseudophakic	648	436	755	449	1.0	0.5
4	F	65	Pseudophakic	489	255	551	353	0.8	0.5
5	M	56	Phakic	821	486	887	420	0.8	0.6
6	F	64	Phakic	961	530	1002	501	1.0	0.5
7	M	70	Pseudophakic	548	299	645	373	1.0	0.5
8	F	63	Phakic	599	330	662	376	1.0	0.6
9	F	75	Pseudophakic	634	436	715	380	1.0	0.0
10	M	70	Phakic	821	523	908	464	0.8	0.5
11	M	75	Pseudophakic	887	467	898	396	0.8	0.5
12	F	67	Phakic	658	386	748	396	0.8	0.5
13	F	73	Phakic	661	336	785	401	1.0	1.0
14	F	71	Phakic	727	468	840	419	1.0	0.5
15	F	68	Phakic	630	351	645	382	0.8	0.5
16	F	72	Phakic	511	244	531	358	0.8	0.5
17	F	70	Phakic	461	237	486	320	1.0	0.5
18	F	77	Phakic	299	207	336	113	0.5	0.0
19	F	66	Phakic	536	282	565	359	1.3	0.8
20	M	68	Phakic	1122	640	1133	505	1.0	0.6
21	F	67	Pseudophakic	1372	798	1384	805	1.3	0.5
Mean				697	402	755	407		
SD				245	144	241	166		

Note: ^aMacular hole diameters are given in μm .

Abbreviations: Preop VA, preoperative visual acuity (logMAR); Postop VA, postoperative visual acuity (logMAR); SD, standard deviation.

more Snellen lines postoperatively. The eye that did not show significant visual improvement at the 6-month postoperative visit was previously one of the stage IV macular holes. Anatomical closure was confirmed with OCT in all the cases. We did not identify any reopenings of the macular holes.

We performed statistical analysis between macular hole parameters and BCVA at 6 months. There was no correlation between minimum diameter (Pearson's correlation coefficient, $r = 0.0067$; $P = 0.97$), maximum diameter (Pearson's correlation coefficient, $r = 0.16$; $P = 0.48$), height of the hole (Pearson's correlation coefficient, $r = 0.25$, $P = 0.26$), and BCVA at 6 months postoperatively.

We also investigated a possible correlation between macular hole parameters and BCVA improvement at 6 months. There was no correlation between minimum diameter (Pearson's correlation coefficient, $r = -0.28$; $P = 0.22$), maximum diameter (Pearson's correlation coefficient, $r = -0.15$; $P = 0.5$), height of the hole (Pearson's correlation coefficient, $r = -0.24$; $P = 0.29$), and BCVA improvement at 6 months postoperatively.

None of the patients had sight-threatening complications during the follow-up period. Four out of the 21 patients had increased IOP on the first postoperative day, which was treated with topical antiglaucoma medication.

Discussion

OCT has helped the clinicians to understand better the subtle relationship between the vitreous and the retina and to measure the dimensions of the macular hole accurately, which is possible due to its high resolution. In addition, OCT can accurately confirm the anatomical closure of the macular hole postoperatively.^{9,10} Macular holes have been classified after surgery as elevated/open, flat/open, and flat/closed.¹¹ In our series of patients, all macular holes were confirmed to be flat/closed.

Surgical intervention is the best management of macular holes as it offers better anatomical and functional results compared to their natural history.^{4,12} Since Kelly and Wendel's pioneer treatment of macular holes,⁴ a combination of different treatment options has been described. ILM peeling plays a pivotal role in the successful management of macular hole surgery (MHS).^{5,10,13–18} Although the use of indocyanine green during ILM peeling has been associated with both retinotoxicity and damage of the retinal tissues,^{16,19–21} it has been shown to achieve better anatomical and visual outcomes when compared with the nonpeeling technique^{10,13,14} especially in large and chronic holes.^{17–19} Interestingly, Margherio et al²² did not show any difference between ILM peeling and the nonpeeling approach in stage II and III macular holes.

In order to avoid the complications of ILM peeling, the use of various adjuvants in MHS has been advocated by many authors. Such adjuvants include transforming growth factor $\beta 2$,^{7,23} serum,^{12,24,25} thrombin,²⁶ and autologous whole blood.²⁷ The most effective adjuvant however seems to be the APC.^{8,27–31} In a randomized, control trial Paques et al⁸ included stage III and IV macular holes in their cohorts and reported a 98% vs 82% anatomical success in the platelet and nonadjuvant groups, respectively. However, there was no statistically significant difference in the visual outcome between the two groups despite the higher rate of anatomical closure in the platelet group. Similarly Hoerauf et al²⁷ report that 93.9% of the macular holes treated with APC showed anatomic success compared to 36.4% success in the group treated with autologous whole blood. They included stage II, III, and IV macular holes in their study and showed that 15 out of 17 stage III macular holes and 6 out of 6 stage IV macular holes achieved anatomic success. Gaudric et al²⁸ also showed better results when platelets were used as adjuvants in MHS (19 of 20 patients in the platelet group had anatomical closure vs 13 of 20 in the nonadjuvant group, all with stage II, III, and IV macular holes) although they recognize that their study is not a randomized controlled trial. Postoperative protocol in all three studies included FDP for 6–12 days. ILM peeling was not performed in any of these studies.

Postoperative FDP for MHS has been an issue of controversy over the years. The initial surgical technique by Kelly and Wendel⁴ involved SF₆ injection and FDP for at least 1 week. Since then FDP was an integral part of a successful MHS, although it can be very demanding for patients of that age group (61 – 77 years) and has been associated with medical complications.³⁰ It was thought that the flotation forces of the bubble keeps the edges of the hole in contact with the retinal pigment epithelium and the FDP optimizes the effect of the bubble on the macular hole. The need for FDP was questioned by Tornambe et al³² who reported 79% anatomical success rate and 55% functional success rate without FDP. They supported the waterproofing theory according to which the gas bubble keeps the macula dry from the vitreous humor. Berger and Brucker³³ showed that keeping the macula dry is more important than the buoyant forces of the bubble on the macula. These forces are actually far higher than the pressure gradient required to keep the retina attached to the choroid. Since then many authors favor the nonposturing approach to MHS.^{34–39} In a recent study, Kapoor et al report 100% anatomical closure of longstanding macular holes in patients who could not maintain FDP with the use of autologous platelets.⁴⁰ A systematic review about

the need for postoperative FDP in MHS concluded that FDP is more useful for the success of MHS in larger idiopathic macular holes.⁴¹

The surgical approach to our series of patients involved standard vitrectomy without ILM peeling. The procedure was augmented with injection of autologous platelets. Internal tamponade was achieved with intravitreal gas injection (C₃F₈). After surgery, all our patients were advised to rest in FDP 1 hour daily for 2 weeks. Patients were asked at every follow up regarding compliance and problems with FDP. None of them reported any medical complications and all of them confirmed that they were compliant with the instructions about posturing. Anatomical closure was confirmed in all cases and the majority of patients experienced improvement in visual acuity of more than two Snellen lines postoperatively. The final visual outcome was achieved 6 months postoperatively. The anatomical success rate of our series of patients is comparable to that of other authors^{8,27,28} who included in their studies stage II, III, and IV macular holes. We also report a high percentage of patients with ≥ 2 lines improvement of their BCVA. However, the final BCVA seems to be lower compared to that of previous publications.^{7,27–29,31} We believe that this may be due to the very poor preoperative BCVA of our series as only one patient had a preoperative BCVA better than 0.8 logMAR. Many of our patients had large and longstanding macular holes, which accounts for the poor preoperative BCVA reported.

Historically, smaller macular holes have been associated with better anatomical and functional results. Previous publications have proposed two prognostic factors for the postoperative visual outcome.^{5,6} Tadayoni et al¹³ found that macular holes $\leq 400 \mu\text{m}$ have 100% anatomical success rate with vitrectomy and gas tamponade followed by FDP for 10 days. On the other hand, holes $\geq 400 \mu\text{m}$ had a better postoperative anatomical outcome if the surgical technique was accompanied by ILM peeling. The level at which they measured the macular holes corresponds to the minimum diameter of the macular hole in our study. Similarly a recent study by Salter et al reported that macular holes with mid-hole diameter of $<500 \mu\text{m}$ had 0% failure rate, while those with a diameter above $1,000 \mu\text{m}$ had a 19.1% reopening rate.⁴²

We included 10 patients in our series with macular holes $\geq 400 \mu\text{m}$ who also had anatomical apposition postoperatively confirmed by OCT. Only one of them had greater than two Snellen lines improvement of their BCVA. We did not find any correlation between macular hole dimensions in BCVA and BCVA improvement. This is in

contrast to a study by Ulrich et al⁶ who reported that BCVA was negatively correlated with minimum and base diameter (maximum diameter in our study). This can be attributed to the small size of our cohort, which makes statistical analysis and conclusions drawn from it less accurate. Furthermore the lack of correlation between macular hole parameters and BCVA improvement is in agreement with the findings of the above-mentioned study.⁶

Our study carries several limitations. It is a retrospective case notes study, which includes a small cohort of patients compared to other studies in the literature. No control group was used and only three large stage IV macular holes were included. It reflects our experience with MHS in our center. However we feel that autologous platelets and 2 weeks of FDP may be considered as a safe adjunctive technique in MHS more so in the case of large holes and when ILM peeling is not performed.

To summarize, we did not find any role of macular hole parameters and indices in the final anatomical or visual outcome in our series as we achieved anatomical closure of all macular holes. Pars plana vitrectomy coupled with autologous injection of platelets and intraocular gas tamponade with postoperative FDP seems to play a major role in the final anatomical and visual outcome in MHS.

Disclosure

The authors report no conflict of interest with any financial organization regarding the material discussed in the manuscript.

References

- Knapp H. Ueber isolierte zerreissungen der aderhaut in folge von traumen auf dem augapfel. *Arch Augenkl. 1869*;1:6–29.
- Hee MR, Puliafito CA, Wong C, et al. Optical coherence tomography of macular holes. *Ophthalmology*. 1995;102(5):748–756.
- Puliafito CA, Hee MR, Lin CP, et al. Imaging of macular diseases with optical coherence tomography. *Ophthalmology*. 1995;102(2):217–229.
- Kelly NE, Wendel RT. Vitreous surgery for idiopathic macular holes. Results of a pilot study. *Arch Ophthalmol*. 1991;109(5):654–659.
- Kusuhara S, Teraoka Escano MF, Fujii S, et al. Prediction of postoperative visual outcome based on hole configuration by optical coherence tomography in eyes with idiopathic macular holes. *Am J Ophthalmol*. 2004;138(5):709–716.
- Ulrich S, Haritoglou C, Gass C, Schaumberger M, Ulbig MW, Kampik A. Macular hole size as a prognostic factor in macular hole surgery. *Br J Ophthalmol*. 2002;86(4):390–393.
- Minihan M, Goggin M, Cleary PE. Surgical management of macular holes: results using gas tamponade alone, or in combination with autologous platelet concentrate, or transforming growth factor beta 2. *Br J Ophthalmol*. 1997;81(12):1073–1079.
- Paques M, Chastang C, Mathis A, et al. Effect of autologous platelet concentrate in surgery for idiopathic macular hole: results of a multicenter, double-masked, randomized trial. Platelets in Macular Hole Surgery Group. *Ophthalmology*. 1999;106(5):932–938.
- Jumper JM, Gallemore RP, McCuen BW 2nd, Toth CA. Features of macular hole closure in the early postoperative period using optical coherence tomography. *Retina*. 2000;20(3):232–237.
- Kwok AK, Lai TY, Yip WW. Correlation of clinical and optical coherence tomography findings in postoperative macular hole closure status. *Ophthalmic Surg Lasers Imaging*. 2003;34(1):25–32.
- Apostolopoulos MN, Koutsandrea CN, Moschos MN, et al. Evaluation of successful macular hole surgery by optical coherence tomography and multifocal electroretinography. *Am J Ophthalmol*. 2002;134(5):667–674.
- Ezra E, Gregor ZJ. Surgery for idiopathic full-thickness macular hole: two-year results of a randomized clinical trial comparing natural history, vitrectomy, and vitrectomy plus autologous serum: Morfields Macular Hole Study Group RAeport no 1. *Arch Ophthalmol*. 2004;122(2):224–236.
- Tadayoni R, Gaudric A, Haouchine B, Massin P. Relationship between macular hole size and the potential benefit of internal limiting membrane peeling. *Br J Ophthalmol*. 2006;90(10):1239–1241.
- Christensen UC, Kroyer K, Sander B, et al. Value of internal limiting membrane peeling in surgery for idiopathic macular hole stage 2 and 3: a randomised clinical trial. *Br J Ophthalmol*. 2009;93(8):1005–1015.
- Park DW, Sipperley JO, Sneed SR, Dugel PU, Jacobsen J. Macular hole surgery with internal-limiting membrane peeling and intravitreal air. *Ophthalmology*. 1999;106(7):1392–1398.
- Haritoglou C, Gass CA, Schaumberger M, Ehrt O, Gandorfer A, Kampik A. Macular changes after peeling of the internal limiting membrane in macular hole surgery. *Am J Ophthalmol*. 2001;132(3):363–368.
- Takebayashi M, Naito T, Matushita S, et al. Long-term outcome of vitrectomy for an idiopathic macular hole performed with the use of indocyanine green. *J Med Invest*. 2008;55(3–4):283–286.
- Al Sabti K, Kumar N, Azad RV. Extended internal limiting membrane peeling in the management of unusually large macular holes. *Ophthalmic Surg Lasers Imaging*. 2009;40(2):185–187.
- Ben Simon GJ, Desatnik H, Alhalel A, Treister G, Moisseiev J. Retrospective analysis of vitrectomy with and without internal limiting membrane peeling for stage 3 and 4 macular hole. *Ophthalmic Surg Lasers Imaging*. 2004;35(2):109–115.
- Gandorfer A, Haritoglou C, Gass CA, Ulbig MW, Kampik A. Indocyanine green-assisted peeling of the internal limiting membrane may cause retinal damage. *Am J Ophthalmol*. 2001;132(3):431–433.
- Sippy BD, Engelbrecht NE, Hubbard GB, et al. Indocyanine green effect on cultured human retinal pigment epithelial cells: implication for macular hole surgery. *Am J Ophthalmol*. 2001;132(3):433–435.
- Margherio RR, Margherio AR, Williams GA, Chow DR, Banach MJ. Effect of perifoveal tissue dissection in the management of acute idiopathic full-thickness macular holes. *Arch Ophthalmol*. 2000;118(4):495–498.
- Glaser BM, Michels RG, Kuppermann BD, Sjaarda RN, Pena RA. Transforming growth factor-beta 2 for the treatment of full-thickness macular holes. A prospective randomized study. *Ophthalmology*. 1992;99(7):1162–1172; discussion 1173.
- Liggett PE, Skolik DS, Horio B, Saito Y, Alfaro V, Mieler W. Human autologous serum for the treatment of full-thickness macular holes. A preliminary study. *Ophthalmology*. 1995;102(7):1071–1076.
- Wells JA, Gregor ZJ. Surgical treatment of full-thickness macular holes using autologous serum. *Eye (Lond)*. 1996;10(Pt 5):593–599.
- Olsen TW, Sternberg P Jr, Capone A Jr, et al. Macular hole surgery using thrombin-activated fibrinogen and selective removal of the internal limiting membrane. *Retina*. 1998;18(4):322–329.
- Hoerauf H, Kluter H, Joachimmeyer E, et al. Results of vitrectomy and the no-touch-technique using autologous adjuvants in macular hole treatment. *Int Ophthalmol*. 2001;24(3):151–159.
- Gaudric A, Massin P, Paques M, et al. Autologous platelet concentrate for the treatment of full-thickness macular holes. *Graefes Arch Clin Exp Ophthalmol*. 1995;233(9):549–554.

29. Korobelnik JF, Hannouche D, Belayachi N, Branger M, Guez JE, Hoang-Xuan T. Autologous platelet concentrate as an adjunct in macular hole healing: a pilot study. *Ophthalmology*. 1996;103(4):590–594.
30. Mulhern MG, Cullinane A, Cleary PE. Visual and anatomical success with short-term macular tamponade and autologous platelet concentrate. *Graefes Arch Clin Exp Ophthalmol*. 2000;238(7):577–583.
31. Vote BJ, Membrey WL, Casswell AG. Autologous platelets for macular hole surgery: the Sussex Eye Hospital experience. *Clin Experiment Ophthalmol*. 2004;32(5):472–477.
32. Tornambe PE, Poliner LS, Grote K. Macular hole surgery without face-down positioning. A pilot study. *Retina*. 1997;17(3):179–185.
33. Berger JW, Brucker AJ. The magnitude of the bubble buoyant pressure: implications for macular hole surgery. *Retina*. 1998;18(1):84–86; author reply 86–88.
34. Dhawahir-Scala FE, Maino A, Saha K, Mokashi AA, McLauchlan R, Charles S. To posture or not to posture after macular hole surgery. *Retina*. 2008;28(1):60–65.
35. Guerrero-Naranjo JL, Cortes-Luna C, Morales-Canton V, et al. Macular hole surgery without postoperative face down positioning. Pilot study. *Arch Soc Esp Oftalmol*. 2006;81(6):321–326.
36. Gupta D. Face-down posturing after macular hole surgery: a review. *Retina*. 2009;29(4):430–443.
37. Mittra RA, Kim JE, Han DP, Pollack JS. Sustained postoperative face-down positioning is unnecessary for successful macular hole surgery. *Br J Ophthalmol*. 2009;93(5):664–666.
38. Simcock PR, Scalia S. Phacovitrectomy without prone posture for full thickness macular holes. *Br J Ophthalmol*. 2001;85(11):1316–1319.
39. Tranos PG, Peter NM, Nath R, et al. Macular hole surgery without prone positioning. *Eye (Lond)*. 2007;21(6):802–806.
40. Kapoor KG, Khan AN, Tieu BC, Khurshid GS. Revisiting autologous platelets as an adjuvant in macular hole repair: chronic macular holes without prone positioning. *Ophthalmic Surg Lasers Imaging*. 2012;43(4):291–295.
41. Solebo AL, Lange CA, Bunce C, Bainbridge JW. Face-down positioning or posturing after macular hole surgery. *Cochrane Database Syst Rev*. 2011;12:CD008228.
42. Salter AB, Folgar FA, Weissbrodt J, Wald KJ. Macular hole surgery prognostic success rates based on macular hole size. *Ophthalmic Surg Lasers Imaging*. 2012;43(3):184–189.

Clinical Ophthalmology

Publish your work in this journal

Clinical Ophthalmology is an international, peer-reviewed journal covering all subspecialties within ophthalmology. Key topics include: Optometry; Visual science; Pharmacology and drug therapy in eye diseases; Basic Sciences; Primary and Secondary eye care; Patient Safety and Quality of Care Improvements. This journal is indexed on

Submit your manuscript here: <http://www.dovepress.com/clinical-ophthalmology-journal>

Dovepress

PubMed Central and CAS, and is the official journal of The Society of Clinical Ophthalmology (SCO). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.